{
  "title": "M21-1, Part V, Subpart iii, Chapter 9 - Hematologic and Lymphatic Systems",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180513/M21-1-Part-V-Subpart-iii-Chapter-9-Hematologic-and-Lymphatic-Systems",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Chapter\nThis chapter contains the following topics:\nTopic\nTopic Name\n1\nSickle Cell Disease\n2\nOther Hematologic and Lymphatic Conditions\n1\n.\nSickle Cell Disease\nIntroduction\nThis topic contains information about hemic and lymphatic conditions, including\ndefinition of\nsickle cell disease\n, and\nsickle cell anemia\ninheritance of\nsickle cell trait\n, and\nsickle cell anemia\ncharacteristics of sickle cell anemia\n, and\nmechanism of inheritance of sickle hemoglobin\n.\nChange Date\nJune 14, 2019\nV.iii.9.1.a\n.\nDefinition:  Sickle Cell Disease\nSickle cell disease\nis a generic term for all disorders characterized by the presence of sickle hemoglobin in the red blood cells and includes\nsickle cell anemia\nsickle cell trait, and\nother hemoglobinopathies such as\nsickle cell thalassemia, and\nsickle-hemoglobin C disease.\nNotes\n:\nThe phenomenon of sickling of red blood cells is a hereditary abnormality that of itself usually produces few ill effects.\nSickle cell trait alone is generally not a ratable disability, as provided in\n38 CFR 4.117, diagnostic code (DC) 7714\n.\nV.iii.9.1.b\n.\nDefinition: Sickle Cell Disease\nSickle cell anemia\nis a hereditary and familial disorder characterized clinically by symptoms of\nanemia\narthritis\nleg ulcers, and\nacute attacks of pain.\nNote\n:  The age of onset is generally early childhood.\nV.iii.9.1.c\n.\nInheritance of Sickle Cell Trait\nInheritance of sickle cell trait may be from one or both parents.\nIf sickle hemoglobin is inherited from one parent and normal hemoglobin from the other, the combination is referred to as sickle cell trait.\nNote\n:  Except for unusual circumstances, this is a benign asymptomatic condition and is not associated with increased morbidity.\nV.iii.9.1.d\n.\nInheritance of Sickle Cell Anemia\nThe inheritance of sickle hemoglobin from each parent results in sickle cell anemia.\nSickle cell anemia is usually accompanied by\nmoderate to severe anemia, and\nappropriate clinical signs and symptoms, such as\nenlargement of the heart\nabnormalities of the musculoskeletal system\nbone and joint pain, and/or\nfever.\nV.iii.9.1.e\n.\nCharacteristics of Sickle Cell Anemia\nSickle cell anemia is a morbid state characterized by hemolytic anemia and the following manifestations\nthe presence of peculiar sickle-shaped, or oat-shaped, red blood cells\nsigns of excessive blood destruction and active blood formation, and\nrepeated vaso-occlusive episodes.\nV.iii.9.1.f\n.\nMechanism of Inheritance of Sickle Hemoglobin\nThe presence of sickle hemoglobin, a variant of the normal hemoglobin in human red blood cells, is subject to the usual mechanisms of biologic inheritance.\n2\n.\nOther Hematologic and Lymphatic Conditions\nIntroduction\nThis topic contains information about hemic and lymphatic conditions, including\nassigning a permanent and total (P&T) evaluation for amyloid light chains (AL) amyloidosis (primary amyloidosis)\nreview examinations of non-Hodgkin’s Lymphoma (NHL) and other persistent cancers\npyramiding of NHL and chronic lymphocytic leukemia (CLL)\ndefinitions of bone marrow and stem cell transplant\nrating schedule update\n, and\nhistorical P&T evaluations\n.\nChange Date\nJune 14, 2019\nV.iii.9.2.a\n.\nAssigning a  P&T Evaluation for AL Amyloidosis\nAssign a permanent and total (P&T) evaluation for amyloid light chains (AL) amyloidosis (primary amyloidosis).  AL amyloidosis is considered incurable and progressive.\nNotes\n:\nEvaluate AL amyloidosis under\n38 CFR 4.117, DC 7717\n.\nConsider ancillary benefits associated with the award of P&T disability evaluations.\nAL amyloidosis is a disability that is presumptively associated with herbicide exposure.\nReferences\n:  For more information on\nrating disabilities associated with herbicide exposure, see\nM21-1, Part VIII, Subpart i, 1.B\n, and\naddressing claims for P&T evaluation based on malignancy prognosis, see\nM21-1, Part V, Subpart ii, 3.D.4.f\n.\nV.iii.9.2.b\n.\nReview Examinations of NHL and Other Persistent Cancers\nWhen evaluating the need for a review examination at the two-year period prescribed in the rating schedule under\n38 CFR 4.117, DC 7715\n, following discontinuance of the treatment phase for non-Hodgkin’s lymphoma (NHL) or any other persistent cancer with a high mortality rate, consider that the various therapeutic treatment modalities may continue at intervals greater than the review period indicated in the rating schedule.\nIf the disease has actively persisted for several years, thoroughly examine the medical record to determine whether the disease is\nactually in remission, or\nstill active and being regularly treated over extended periods of time.\nDo\nnot\nschedule a review examination unless the record clearly shows a long-term and stable remission.\nImportant\n:  Consider assigning a P&T evaluation when a provision under\n38 CFR 3.327(b)(2)\napplies or as otherwise warranted under the provisions of\nM21-1, Part V, Subpart ii, 3.D.4\n.\nReference\n:  For more information on when not to schedule a review examination, see\nM21-1, Part IV, Subpart i, 2.G\n.\nV.iii.9.2.c\n.\nPyramiding of CLL and NHL\nDo not assign separate evaluations for chronic lymphocytic leukemia (CLL) (\n38 CFR 4.117, DC 7703\n) and NHL (\n38 CFR 4.117, DC 7715\n).  They are cancers of the same body system and assignment of multiple evaluations would be pyramiding.\nIn cases where both cancers are diagnosed, assign the appropriate evaluation using a hyphenated DC.\nReferences\n:  For more information on\npyramiding, see\nM21-1, Part V, Subpart ii, 3.D.2.b\n, and\npresumptive service connection for CLL and NHL, see\nM21-1, Part VIII, Subpart i, 1.B.1\n.\nV.iii.9.2.d\n.\nDefinition:  Bone Marrow and Stem Cell Transplant\nA\nbone marrow transplant\n, also called a\nstem cell transplant\n, is a procedure used to infuse healthy cells, called stem cells, into the body to replace damaged or diseased bone marrow.  The process of infusing healthy cells into the body to replace diseased tissue may be referred to in a variety of manners based on the donor source and the type of tissue used.  The following procedures all satisfy the criteria for the 100-percent rating under\n38 CFR 4.117\n:\nstem cell transplant\nbone marrow transplant\nbone marrow stem cell transplant\nperipheral blood transplant, and\nperipheral blood stem cell transplant.\nV.iii.9.2.e\n.\nRating Schedule Update\nThe criteria for rating disabilities of the hematologic and lymphatic systems in\n38 CFR 4.117\nwere most recently updated effective\nDecember 9, 2018, and\nOctober 23, 1995.\nThe purpose of these updates was to\nincorporate medical advances\nupdate medical terminology\nadd disabilities not previously included, and\nrefine rating criteria.\nNote\n:  These updates were not liberalizing changes in the rating criteria.\nReference\n:  For more information on these and other historical changes to\n38 CFR 4.117\n, see\n38 CFR 4, Appendix A\n38 CFR 4.117 (Historical)\n, and\nthe\nBoard of Veterans Appeal Research Tools\nwebsite for historical\n38 CFR 4.117\n.\nV.iii.9.2.f\n.\nHistorical P&T Evaluations\nHistorical policy guidance in existence prior to the December 9, 2018, rating schedule update directed the assignment of P&T evaluations for CLL and multiple myeloma.  P&T evaluations assigned under the prior version of the rating schedule with application of those policies are protected under\n38 CFR 3.951(a)\n.\nP&T evaluations were directed\nfrom November 6, 2003, to December 9, 2018, for CLL, with diagnosis being the sole requirement unless the condition was considered cured via treatment with a bone marrow transplant, and\nfrom January 28, 2003, to December 9, 2018, for multiple myeloma unless an exceptional situation was present in which inactive multiple myeloma was documented.\nImportant\n:\nIn all situations, the evidence of record must be analyzed to determine the treatment plan and prognosis for active malignancy associated with CLL or multiple myeloma.  As directed in\nM21-1, Part V, Subpart ii, 3.D.4\n, assign a P&T evaluation for active malignancy when warranted, whether the disability is evaluated under historical or current rating criteria.\nRevisions to\n38 CFR 4.117, DCs 7703 and 7712\neffective on December 9, 2018, provide criteria for scheduling review examinations for CLL and multiple myeloma unless there is clear evidence establishing a terminal prognosis.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000180879\" articlename=\"M21-1, Part V, Subpart iii, Chapter 8, Section B - Disabilities of the Breast\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180879/M21-1-Part-V-Subpart-iii-Chapter-8-Section-B-Disabilities-of-the-Breast\">&lt;-- Previous Section</a></span></span><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\">  <a articleid=\"554400000180515\" articlename=\"M21-1, Part V, Subpart iii, Chapter 10 - Skin Conditions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180515/M21-1-Part-V-Subpart-iii-Chapter-10-Skin-Conditions\">Next Section --&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Chapter</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This chapter contains the following topics:</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 500px; border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\"><thead><tr><th scope=\"col\" style=\"width: 86px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic</strong></span></span></div></th><th scope=\"col\" style=\"width: 423px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic Name</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 86px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1 </span></span></div></td><td style=\"width: 423px; vertical-align: middle; padding: 1px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\">Sickle Cell Disease</span></a></span></div></td></tr><tr><td style=\"width: 86px; text-align: center; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"width: 423px; vertical-align: middle; padding: 1px;\"><div><a href=\"#2\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Other Hematologic and Lymphatic Conditions</span></span></a></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><h2 class=\"ng-scope\"> <br/> </h2><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial, helvetica, sans-serif\">1<a id=\"1\" name=\"1\">.</a>  Sickle Cell Disease</span></span></h2><p class=\"ng-scope\"> <br/> </p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information about hemic and lymphatic conditions, including</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">definition of </span></span><ul><li><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">sickle cell disease</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">, and</span></span></li><li><a href=\"#1b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">sickle cell anemia</span></span></a></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">inheritance of </span></span><ul><li><a href=\"#1c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">sickle cell trait</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">, and</span></span></li><li><a href=\"#1d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">sickle cell anemia</span></span></a></li></ul></li><li><a href=\"#1e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">characteristics of sickle cell anemia</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">, and</span></span></li><li><a href=\"#1f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">mechanism of inheritance of sickle hemoglobin</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">June 14, 2019</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.1.a<a id=\"1a\" name=\"1a\">.</a> Definition:  Sickle Cell Disease</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Sickle cell disease</em></strong> is a generic term for all disorders characterized by the presence of sickle hemoglobin in the red blood cells and includes</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sickle cell anemia</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sickle cell trait, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">other hemoglobinopathies such as </span></span></div><ul><li style=\"text-align: justify\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sickle cell thalassemia, and</span></span></div></li><li style=\"text-align: justify\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sickle-hemoglobin C disease. </span></span></div></li></ul></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>:  </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The phenomenon of sickling of red blood cells is a hereditary abnormality that of itself usually produces few ill effects.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Sickle cell trait alone is generally not a ratable disability, as provided in <a href=\"https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=155ff03385856e04203a2c76ad88b15e&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_1117\" target=\"_blank\">38 CFR 4.117, diagnostic code (DC) 7714</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.1.b<a id=\"1b\" name=\"1b\">.</a> Definition: Sickle Cell Disease</span></span></span></span></h3><h3><strong><strong><strong><strong> </strong></strong></strong></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Sickle cell anemia</em></strong> is a hereditary and familial disorder characterized clinically by symptoms of</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">anemia</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">arthritis</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">leg ulcers, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">acute attacks of pain. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  The age of onset is generally early childhood. </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.1.c<a id=\"1c\" name=\"1c\">.</a> Inheritance of Sickle Cell Trait</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Inheritance of sickle cell trait may be from one or both parents.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If sickle hemoglobin is inherited from one parent and normal hemoglobin from the other, the combination is referred to as sickle cell trait. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Except for unusual circumstances, this is a benign asymptomatic condition and is not associated with increased morbidity.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.1.d<a id=\"1d\" name=\"1d\">.</a> Inheritance of Sickle Cell Anemia</span></span></span></span></h3><p></p></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The inheritance of sickle hemoglobin from each parent results in sickle cell anemia.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Sickle cell anemia is usually accompanied by</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">moderate to severe anemia, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">appropriate clinical signs and symptoms, such as </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">enlargement of the heart</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">abnormalities of the musculoskeletal system</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">bone and joint pain, and/or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">fever.</span></span></div></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.1.e<a id=\"1e\" name=\"1e\">.</a> Characteristics of Sickle Cell Anemia</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Sickle cell anemia is a morbid state characterized by hemolytic anemia and the following manifestations</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the presence of peculiar sickle-shaped, or oat-shaped, red blood cells</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">signs of excessive blood destruction and active blood formation, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">repeated vaso-occlusive episodes.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" spellcheck=\"false\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.1.f<a id=\"1f\" name=\"1f\">.</a> Mechanism of Inheritance of Sickle Hemoglobin</span></span></span></span></h3><p></p></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The presence of sickle hemoglobin, a variant of the normal hemoglobin in human red blood cells, is subject to the usual mechanisms of biologic inheritance.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><h2 class=\"ng-scope\"> <br/> <span style=\"font-size: 16px\"><span style=\"font-family: arial, helvetica, sans-serif\">2<a id=\"2\" name=\"2\">.</a>  Other Hematologic and Lymphatic Conditions</span></span></h2><p class=\"ng-scope\"> <br/> </p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information about hemic and lymphatic conditions, including</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2a\" target=\"_self\">assigning a permanent and total (P&amp;T) evaluation for amyloid light chains (AL) amyloidosis (primary amyloidosis)</a></span></span></li><li><a href=\"#2b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">review examinations of non-Hodgkin’s Lymphoma (NHL) and other persistent cancers</span></span></a></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2c\" target=\"_self\">pyramiding of NHL and chronic lymphocytic leukemia (CLL)</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2d\" target=\"_self\">definitions of bone marrow and stem cell transplant</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2e\" target=\"_self\">rating schedule update</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2f\" target=\"_self\">historical P&amp;T evaluations</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">June 14, 2019</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.9.2.a<a name=\"2a\">.</a> Assigning a  P&amp;T Evaluation for AL Amyloidosis</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Assign a permanent and total (P&amp;T) evaluation for amyloid light chains (AL) amyloidosis (primary amyloidosis).  AL amyloidosis is considered incurable and progressive.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Evaluate AL amyloidosis under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=92398e0de1640534d66e4a66e3188669&amp;mc=true&amp;node=se38.1.4_1117&amp;rgn=div8\" target=\"_blank\">38 CFR 4.117, DC 7717</a>.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Consider ancillary benefits associated with the award of P&amp;T disability evaluations.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">AL amyloidosis is a disability that is presumptively associated with herbicide exposure.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">rating disabilities associated with herbicide exposure, see <a articleid=\"554400000177423\" articlename=\"M21-1, Part VIII, Subpart i, Chapter 1, Section B - Ratings for Disabilities Associated with Herbicide Exposure\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177423/M21-1-Part-VIII-Subpart-i-Chapter-1-Section-B-Ratings-for-Disabilities-Associated-with-Herbicide-Exposure\">M21-1, Part VIII, Subpart i, 1.B</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">addressing claims for P&amp;T evaluation based on malignancy prognosis, see <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.4.f</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.2.b<a id=\"2b\" name=\"2b\">.</a> Review Examinations of NHL and Other Persistent Cancers</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When evaluating the need for a review examination at the two-year period prescribed in the rating schedule under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=bdbc1eef3a9816189007dd0ac2a2bc18&amp;mc=true&amp;node=se38.1.4_1117&amp;rgn=div8\" target=\"_blank\">38 CFR 4.117, DC 7715</a>, following discontinuance of the treatment phase for non-Hodgkin’s lymphoma (NHL) or any other persistent cancer with a high mortality rate, consider that the various therapeutic treatment modalities may continue at intervals greater than the review period indicated in the rating schedule.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If the disease has actively persisted for several years, thoroughly examine the medical record to determine whether the disease is</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">actually in remission, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">still active and being regularly treated over extended periods of time.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Do <strong><em>not</em></strong> schedule a review examination unless the record clearly shows a long-term and stable remission.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>:  Consider assigning a P&amp;T evaluation when a provision under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=bdbc1eef3a9816189007dd0ac2a2bc18&amp;mc=true&amp;node=se38.1.3_1327&amp;rgn=div8\" target=\"_blank\">38 CFR 3.327(b)(2)</a> applies or as otherwise warranted under the provisions of <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.4</a>.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on when not to schedule a review examination, see <a articleid=\"554400000180510\" articlename=\"M21-1, Part IV, Subpart i, Chapter 2, Section G - Historical\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180510/M21-1-Part-IV-Subpart-i-Chapter-2-Section-G-Historical\">M21-1, Part IV, Subpart i, 2.G</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.9.2.c<a id=\"2c\" name=\"2c\">.</a>  Pyramiding of CLL and NHL</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Do not assign separate evaluations for chronic lymphocytic leukemia (CLL) (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=d119b8c22185448824f34f1c8e057b69&amp;mc=true&amp;node=se38.1.4_1117&amp;rgn=div8\" target=\"_blank\">38 CFR 4.117, DC 7703</a>) and NHL (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=d119b8c22185448824f34f1c8e057b69&amp;mc=true&amp;node=se38.1.4_1117&amp;rgn=div8\" target=\"_blank\">38 CFR 4.117, DC 7715</a>).  They are cancers of the same body system and assignment of multiple evaluations would be pyramiding. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In cases where both cancers are diagnosed, assign the appropriate evaluation using a hyphenated DC.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">pyramiding, see <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.b</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">presumptive service connection for CLL and NHL, see <a articleid=\"554400000177423\" articlename=\"M21-1, Part VIII, Subpart i, Chapter 1, Section B - Ratings for Disabilities Associated with Herbicide Exposure\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177423/M21-1-Part-VIII-Subpart-i-Chapter-1-Section-B-Ratings-for-Disabilities-Associated-with-Herbicide-Exposure\">M21-1, Part VIII, Subpart i, 1.B.1</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.2.d<a id=\"2d\" name=\"2d\">.</a> Definition:  Bone Marrow and Stem Cell Transplant</span></span></span></span></h3><p></p></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">A <strong><em>bone marrow transplant</em></strong>, also called a <strong><em>stem cell transplant</em></strong>, is a procedure used to infuse healthy cells, called stem cells, into the body to replace damaged or diseased bone marrow.  The process of infusing healthy cells into the body to replace diseased tissue may be referred to in a variety of manners based on the donor source and the type of tissue used.  The following procedures all satisfy the criteria for the 100-percent rating under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=40b22f5c765ab034b79d6b92e7b10fbb&amp;mc=true&amp;node=se38.1.4_1117&amp;rgn=div8\" target=\"_blank\">38 CFR 4.117</a>:</span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">stem cell transplant</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">bone marrow transplant</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">bone marrow stem cell transplant</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">peripheral blood transplant, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">peripheral blood stem cell transplant.</span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.2.e<a id=\"2e\" name=\"2e\">.</a>  Rating Schedule Update</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The criteria for rating disabilities of the hematologic and lymphatic systems in <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=17a7d596f39f14c4ff2256382742f829&amp;mc=true&amp;node=se38.1.4_1117&amp;rgn=div8\" target=\"_blank\">38 CFR 4.117</a> were most recently updated effective </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">December 9, 2018, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">October 23, 1995.  </span></span></li></ul><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The purpose of these updates was to</span></span></p><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">incorporate medical advances</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">update medical terminology</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">add disabilities not previously included, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">refine rating criteria.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  These updates were not liberalizing changes in the rating criteria. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on these and other historical changes to <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=17a7d596f39f14c4ff2256382742f829&amp;mc=true&amp;node=se38.1.4_1117&amp;rgn=div8\" target=\"_blank\">38 CFR 4.117</a>, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=17a7d596f39f14c4ff2256382742f829&amp;mc=true&amp;node=ap38.1.4_1150.a&amp;rgn=div9\" target=\"_blank\">38 CFR 4, Appendix A</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=90efe403df8497ca8cb316b192541b97&amp;pitd=20181207&amp;node=se38.1.4_1117&amp;rgn=div8\" target=\"_blank\">38 CFR 4.117 (Historical)</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the <a href=\"http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3aproject=lsa-bva-counsel-judge-project&amp;v%3asources=lsa-bva-citator-regulation-collection&amp;frontpage=1&amp;v%3aframe=form&amp;\" target=\"_blank\">Board of Veterans Appeal Research Tools</a> website for historical <a href=\"http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3Asources=lsa-bva-citator-regulation-collection&amp;v%3Aproject=lsa-bva-counsel-judge-project&amp;lnquery=38+CFR+4.117&amp;lnfilters=&amp;chkbxfilters=&amp;query=%28%2238+cfr+4.117%22%29&amp;querytype=boolean\" target=\"_blank\">38 CFR 4.117</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.9.2.f<a id=\"2f\" name=\"2f\">.</a>  Historical P&amp;T Evaluations</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Historical policy guidance in existence prior to the December 9, 2018, rating schedule update directed the assignment of P&amp;T evaluations for CLL and multiple myeloma.  P&amp;T evaluations assigned under the prior version of the rating schedule with application of those policies are protected under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=0dbeb526a7f9c320a8f55694e1a45e9e&amp;mc=true&amp;node=se38.1.3_1951&amp;rgn=div8\" target=\"_blank\">38 CFR 3.951(a)</a>. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">P&amp;T evaluations were directed</span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">from November 6, 2003, to December 9, 2018, for CLL, with diagnosis being the sole requirement unless the condition was considered cured via treatment with a bone marrow transplant, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">from January 28, 2003, to December 9, 2018, for multiple myeloma unless an exceptional situation was present in which inactive multiple myeloma was documented.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>:  </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In all situations, the evidence of record must be analyzed to determine the treatment plan and prognosis for active malignancy associated with CLL or multiple myeloma.  As directed in <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.4</a>, assign a P&amp;T evaluation for active malignancy when warranted, whether the disability is evaluated under historical or current rating criteria. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Revisions to <a href=\"https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=155ff03385856e04203a2c76ad88b15e&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_1117\" target=\"_blank\">38 CFR 4.117, DCs 7703 and 7712</a> effective on December 9, 2018, provide criteria for scheduling review examinations for CLL and multiple myeloma unless there is clear evidence establishing a terminal prognosis.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000180879\" articlename=\"M21-1, Part V, Subpart iii, Chapter 8, Section B - Disabilities of the Breast\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180879/M21-1-Part-V-Subpart-iii-Chapter-8-Section-B-Disabilities-of-the-Breast\">&lt;-- Previous Section</a></span></span><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\">  <a articleid=\"554400000180515\" articlename=\"M21-1, Part V, Subpart iii, Chapter 10 - Skin Conditions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180515/M21-1-Part-V-Subpart-iii-Chapter-10-Skin-Conditions\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3Asources=lsa-bva-citator-regulation-collection&v%3Aproject=lsa-bva-counsel-judge-project&lnquery=38+CFR+4.117&lnfilters=&chkbxfilters=&query=%28%2238+cfr+4.117%22%29&querytype=boolean",
    "http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3aproject=lsa-bva-counsel-judge-project&v%3asources=lsa-bva-citator-regulation-collection&frontpage=1&v%3aframe=form&",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=40b22f5c765ab034b79d6b92e7b10fbb&mc=true&node=se38.1.4_1117&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=92398e0de1640534d66e4a66e3188669&mc=true&node=se38.1.4_1117&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=bdbc1eef3a9816189007dd0ac2a2bc18&mc=true&node=se38.1.3_1327&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=bdbc1eef3a9816189007dd0ac2a2bc18&mc=true&node=se38.1.4_1117&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=d119b8c22185448824f34f1c8e057b69&mc=true&node=se38.1.4_1117&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=155ff03385856e04203a2c76ad88b15e&mc=true&r=SECTION&n=se38.1.4_1117",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=0dbeb526a7f9c320a8f55694e1a45e9e&mc=true&node=se38.1.3_1951&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=17a7d596f39f14c4ff2256382742f829&mc=true&node=ap38.1.4_1150.a&rgn=div9",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=17a7d596f39f14c4ff2256382742f829&mc=true&node=se38.1.4_1117&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=90efe403df8497ca8cb316b192541b97&pitd=20181207&node=se38.1.4_1117&rgn=div8"
  ],
  "scraped_at": "2025-06-16T22:45:35.239285",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180515/M21-1-Part-V-Subpart-iii-Chapter-10-Skin-Conditions"
}